MeSH term
Frequency | Condition_Probility | Aged | 24 | 0.0 |
Androgens/metabolism | 3 | 4.0 |
Biological Markers | 2 | 0.0 |
Case-Control Studies | 9 | 0.0 |
Cholestenone 5 alpha-Reductase | 14 | 53.0 |
Dihydrotestosterone/metabolism | 3 | 5.0 |
Humans | 62 | 0.0 |
Male | 51 | 0.0 |
Middle Aged | 29 | 0.0 |
Oxidoreductases/*genetics | 9 | 9.0 |
*Polymorphism, Genetic | 18 | 0.0 |
Research Support, Non-U.S. Gov't | 36 | 0.0 |
Trinucleotide Repeats | 3 | 2.0 |
Adult | 20 | 0.0 |
Alleles | 9 | 0.0 |
Androgens/physiology | 2 | 4.0 |
Body Mass Index | 3 | 0.0 |
Female | 16 | 0.0 |
Genetic Predisposition to Disease | 8 | 0.0 |
Genotype | 26 | 0.0 |
Haplotypes/genetics | 2 | 0.0 |
Menopause | 2 | 0.0 |
*Mutation, Missense | 5 | 0.0 |
*Point Mutation | 4 | 0.0 |
Risk | 5 | 0.0 |
Risk Factors | 14 | 0.0 |
Age Factors | 3 | 0.0 |
European Continental Ancestry Group | 2 | 0.0 |
Heterozygote | 5 | 0.0 |
Neoplasm Staging | 4 | 0.0 |
Odds Ratio | 6 | 0.0 |
Polymerase Chain Reaction | 12 | 0.0 |
Prostate-Specific Antigen/metabolism | 2 | 5.0 |
Prostatic Neoplasms/enzymology/etiology/*genetics | 2 | 100.0 |
Testosterone 5-alpha-Reductase/*genetics | 24 | 88.0 |
Adolescent | 6 | 0.0 |
Phenotype | 5 | 0.0 |
Polymorphism, Restriction Fragment Length | 5 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Genetic Markers | 2 | 0.0 |
Haplotypes | 2 | 0.0 |
Oxidoreductases/genetics | 2 | 5.0 |
Prostatic Neoplasms/*genetics | 6 | 3.0 |
Receptors, Androgen/genetics | 3 | 5.0 |
Steroid 17-alpha-Hydroxylase/genetics | 4 | 14.0 |
*Genetic Predisposition to Disease | 5 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 18 | 0.0 |
Polymorphism, Genetic | 8 | 0.0 |
Receptors, Androgen/*genetics | 5 | 4.0 |
Steroid 17-alpha-Hydroxylase/*genetics | 7 | 21.0 |
Testosterone/*blood | 2 | 0.0 |
Genetic Predisposition to Disease/genetics | 3 | 0.0 |
Aged, 80 and over | 6 | 0.0 |
Prostatic Neoplasms/epidemiology/*genetics/metabolism | 2 | 66.0 |
Amino Acid Substitution | 4 | 0.0 |
Base Sequence | 10 | 0.0 |
Polymorphism, Single-Stranded Conformational | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Codon/genetics | 3 | 0.0 |
Gene Frequency | 8 | 0.0 |
Neoplasm Proteins/genetics | 2 | 0.0 |
Linkage (Genetics) | 3 | 0.0 |
Prostatic Hyperplasia/enzymology/*genetics | 2 | 50.0 |
Prostatic Neoplasms/enzymology/*genetics/pathology | 2 | 28.0 |
Variation (Genetics) | 5 | 0.0 |
Androgens/*blood | 2 | 1.0 |
*Genetic Screening | 2 | 1.0 |
Incidence | 3 | 0.0 |
Molecular Sequence Data | 7 | 0.0 |
Multivariate Analysis | 2 | 0.0 |
Probability | 2 | 0.0 |
Risk Assessment | 5 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
Cohort Studies | 4 | 0.0 |
Prostate-Specific Antigen/analysis | 2 | 4.0 |
Survival Analysis | 2 | 0.0 |
Finasteride/therapeutic use | 3 | 100.0 |
Germ-Line Mutation | 2 | 0.0 |
Polymorphism, Single Nucleotide/genetics | 2 | 0.0 |
Prostatic Hyperplasia/*genetics/metabolism | 2 | 66.0 |
Testosterone 5-alpha-Reductase/*genetics/metabolism | 2 | 100.0 |
Androgens/genetics/*metabolism | 2 | 66.0 |
Anticarcinogenic Agents/therapeutic use | 2 | 13.0 |
Child | 4 | 0.0 |
Child, Preschool | 4 | 0.0 |
Infant | 5 | 0.0 |
Testosterone/blood | 2 | 0.0 |
DNA, Neoplasm/*genetics | 3 | 1.0 |
Point Mutation | 2 | 0.0 |
Prognosis | 4 | 0.0 |
Prostate-Specific Antigen/blood | 3 | 3.0 |
Prostatectomy | 2 | 2.0 |
English Abstract | 2 | 0.0 |
Prostatic Neoplasms/*epidemiology/*genetics | 2 | 28.0 |
Breast Neoplasms/*enzymology | 2 | 3.0 |
Progesterone/*metabolism | 2 | 5.0 |
Testosterone 5-alpha-Reductase/genetics | 3 | 100.0 |
African Continental Ancestry Group/genetics | 2 | 0.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
Comparative Study | 3 | 0.0 |
European Continental Ancestry Group/genetics | 2 | 0.0 |
Isoenzymes/*genetics | 2 | 0.0 |
Testosterone/metabolism | 2 | 1.0 |
Exons | 2 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Family Health | 2 | 0.0 |
Homozygote | 2 | 0.0 |
Mutation | 3 | 0.0 |
Pedigree | 2 | 0.0 |
Pseudohermaphroditism/*genetics | 2 | 14.0 |
Chromosome Mapping | 2 | 0.0 |
*Genes, Structural | 2 | 0.0 |
Infant, Newborn | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Genetic Predisposition to Disease/*genetics | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 3 | 0.0 |
Cytochrome P-450 Enzyme System/*genetics | 2 | 0.0 |
Cross-Sectional Studies | 2 | 0.0 |
Enzyme Inhibitors/therapeutic use | 2 | 2.0 |
Prostatic Hyperplasia/genetics | 2 | 10.0 |
Japan | 3 | 0.0 |
